Acute psychological and physiological affects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study

Psychopharmacology

Volumn 172, Issue 2, 2004, Pages 145-156

  Hasler, Felix ^a   Grimberg, Ulrike ^a   Benz, Marco A ^a   Huber, Theo ^a   Vollenweider, Franz X ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Altered states of consciousness; Cardiovascular effects; Dose effect study; Neuroendocrinology; Psilocybin; Psycho(patho)logy

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PLACEBO; PROLACTIN; PSILOCYBINE; THYROTROPIN;

ADJECTIVE MOOD RATING SCALE; ALERTNESS; ALTERED STATES OF CONSCIOUSNESS RATING SCALE; ARTICLE; BODY TEMPERATURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EGO; ELECTROCARDIOGRAM; FEMALE; FRANKFURT ATTENTION INVENTORY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; MOOD; NEUROENDOCRINOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; RATING SCALE; THYROTROPIN BLOOD LEVEL;

ADULT; AFFECT; ANALYSIS OF VARIANCE; ATTENTION; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; PSILOCYBINE;

EID: 1642273671     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1640-6     Document Type: Article

References (53)

1. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S
2. Bonini P, Ceriotti F, Keller F, Brauer P, Stolz H, Pascual C, Garcia-Beltran L, Vonderschmitt DJ, Pei P (1992) Multicentre evaluation of the Boehringer Mannheim/Hitachi 747 analysis system. Eur J Clin Chem Clin Biochem 30:881-899
3. Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210-221
4. Creese I, Burt DR, Snyder SH (1975) The dopamine receptor, differential binding of d-LSD and related agents to agonist and antagonist states. Life Sci 17:1715-1719
5. Cuomo MJ, Dyment PG, Gammino VM (1994) Increasing use of 'ecstasy' (MDMA) and other hallucinogens on a college campus. Am College Health 42:271-274
6. Derogatis LR, Lipman RS, Covi L (1973) SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharm Bull 9:13-28
7. Dittrich A (1993) Psychological aspects of altered states of consciousness of the LSD type: measurement of their basic dimensions and prediction of individual differences. In: Pletscher A, Ladewig D (eds) Fifty years of LSD. Current status and perspectives of hallucinogens. Parthenon, New York, pp 101-118
8. Dittrich A (1996) Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. VWB Verlag, Berlin
9. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychology 31:80-84
10. Dittrich A, Lamparter D, Maurer M (1999) 5D-ABZ: Fragebogen zur Erfassung Aussergewöhnlicher Bewusstseinszustände. Eine kurze Einführung. PSIN Plus, Zürich
11. Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA, Macher JP (1999) Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 24:695-712
12. Ellis KA, Nathan PJ (2001) The pharmacology of human working memory. Int J Neuropsychopharmacol 4:299-313
13. Fahrenberg J, Hampel R, Selg H (1984) Das Freiburger Persö nlichkeitsinventar FPI. D-Göttingen, Hogrefe
14. Fried R (2000) Aspartatamino-transferase (AST, ASAT, GOT) im Plasma. Manual of the Institute of Clinical Chemistry of the University Hospital of Zürich. Zürich
15. Fuller RW (1981) Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32:118-127
16. Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, Geyer MA (1998) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol 9:561-566
17. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methlyenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 142:41-50
18. Hasler F (1997) Untersuchungen zur Humanpharmakokinetik von Psilocybin. Thesis, University of Bern
19. Hasler F, Bourquin D, Brenneisen R, Baer T, Vollenweider FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72:175-184
20. Hollister LE (1961) Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmacodyn Ther 130:42-53
21. Holmes MC, DiRenzo GD, Beckford B, Gillham B, Jones MT (1982) Role of serotonin in the control of secretion of corticotropin releasing factor. J Endocrinol 93:151-160
22. Isbell H (1959) Comparison of reactions induced by psilocybin and LSD-25 in man. Psychopharmacology 1:29-38
23. Janke W, Debus G (1978) Die Eigenschaftswörterliste (EWL-K) - Ein Verfahren zur Erfassung der Befindlichkeit. Hogrefe, Göttingen
24. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
25. Knedel M, Haeckel R, Seidel D, Thiery J, Vonderschmitt DJ, Haenseler E (1986) Analytical performance of the random access analyser Hitachi 737. A multicentre evaluation. J Clin Chem Clin Biochem 24:409-432
26. Krulich L (1982) Neurotransmitter control of thyrotropin secretion. Neuroendocrinology 35:139-147
27. Laux L, Glanzmann P, Schaffner P, Spielberger CD (1981) Das State-Trait-Angstinventar (STAI). Beltz, Weinheim
28. Lindenblatt H, Kraemer E, Holzmann-Erens P, Gouzoulis-Mayfrank E, Kovar KA (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction. J Chromatogr B 709:255-263
29. Lohrer F, Albers M (1999) Biological drugs - is there a change in substance abuse? Psychiatr Prax 26:199-201
30. Mannisto PT (1983) Central regulation of thyrotropin secretion in rats: methodological aspects, problems and some progress. Med Biol 61:92-100
31. Marek GJ, Aghajanian GK (1998) Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend 51:189-198
32. McKenna DJ, Repke DB, Lo L, Peroutka SJ (1990) Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29:193-198
33. Meltzer HY, Nash JF (1988) Serotonin and mood: neuroendocrine aspects. In: Ganten D, Pfaff D (eds) Neuroendocrinology of mood. Springer, Berlin Heidelberg New York, pp 183-210
34. Meneses A (1998) Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Rev Neurosci 4:275-289
35. Mitsuma T, Nogimori T (1983) Effects of serotonergic system on hypothalamic-pituitary-thyroid axis in rats. Horm Metab Res 15:346-349
36. Moosbrugger H, Oehlschlägel J (1996) FAIR Frankfurter Aufmerksamkeitsinventar. Testmanual, Hans Huber, Göttingen
37. O'Malley BP, Jennings PE, Cook N, Barnett DB, Rosenthal FD (1984) The role of serotonin (5-HT) in the control of TSH and prolactin release in euthyroid subjects assessed by the administration of ketanserin (5-HT2 antagonist) and zimelidine (5-HT re-uptake inhibitor). Psychoneuroendocrinology 9:13-19
38. Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357-364
39. Prescott RW, Kendall-Taylor P, Weightman DR, Watson MJ, Ratcliffe WA (1984) The effect of ketanserin, a specific serotonin antagonist on the PRL, HG, ACTH and cortisol response to hypoglycaemia in normal subjects. Clin Endocrinol 20:137-142
40. Ramage AG (2001) Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res Bull 56:425-439
41. Robinson AG, Nelson PB (1983) Prolactinomas in women: current therapies. Ann Int Med 99:115-118
42. Scharfetter C (1981) Ego-psychopathology: the concept and its empirical evaluation. Psychol Med 11:273-280
43. Silva JD, Nunes MT (1996) Facilitatory role of serotonin (5-HT) in the control of thyrotropin releasing hormone/throtropin (TRH/ TSH) secretion in rats. Braz J Med Biol Res 29:677-683
44. Strassman RJ, Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 51:85-97
45. Supprian T, Supprian R, Rosler M, Wanke K (2001) Psychoactive mushrooms - an update. Fortschr Neurol Psychiatr 69:597-602
46. Van de Kar LD, Karteszi M, Bethea CL, Ganong WF (1985) Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 41:380-384
47. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Thackery SG (2001) 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21:3572-3579
48. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507
49. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372
50. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neurore-port 9:3897-3902
51. 11C)raclopride. Neuropsychopharmacology 20:424-433
52. 2A receptors in working memory. J Neurosci 22:2843-2854
53. Wittchen HU, Pfister H (1997) DIA-X-Interview. Swet Test Services, Frankfurt